A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia
- PMID: 2201728
A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia
Abstract
A double-blind study comparing zopiclone and triazolam, in 48 healthy, chronic insomniacs, was undertaken in two centers to compare the hypnotic and withdrawal effects of both compounds. Comparable doses of 7.5 mg zopiclone and 0.25 mg triazolam were given at bedtime for 21 nights after a 3 day wash-out period, followed by 4 placebo nights of withdrawal monitoring. During the investigation, a 17 item post-sleep questionnaire was completed daily, the Clinical Global Impression (CGI) scale weekly, and the Hamilton Anxiety Scale (HAM-A) at baseline and at the end of the study. Withdrawal effects were evaluated with a withdrawal symptom checklist and the CGI (withdrawal). Results indicated that both compounds improved sleep and were equally effective. However, a larger number of triazolam subjects withdrew from the study because of ineffectiveness or adverse side-effects. A greater number of zopiclone subjects experienced a transient modification of taste which disappeared with discontinuation of therapy. Significant deterioration in nearly all sleep parameters were noted after the first withdrawal night of triazolam; much fewer modifications of sleep parameters were observed following the discontinuation of zopiclone.
Similar articles
-
Zopiclone versus triazolam in insomniac geriatric patients: a specific increase in delta sleep with zopiclone.Int Clin Psychopharmacol. 1990 Apr;5 Suppl 2:47-55. Int Clin Psychopharmacol. 1990. PMID: 2201730 Clinical Trial.
-
Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs.Int Clin Psychopharmacol. 1990 Apr;5 Suppl 2:39-46. Int Clin Psychopharmacol. 1990. PMID: 2201729 Clinical Trial.
-
A comparative study of zopiclone and triazolam in patients with insomnia.Int Clin Psychopharmacol. 1990 Apr;5 Suppl 2:21-7. Int Clin Psychopharmacol. 1990. PMID: 2201727 Clinical Trial.
-
Zopiclone, the third generation hypnotic: a clinical overview.Int Clin Psychopharmacol. 1990 Apr;5 Suppl 2:147-58. Int Clin Psychopharmacol. 1990. PMID: 2201726 Review.
-
Rebound insomnia: a critical review.J Clin Psychopharmacol. 1989 Jun;9(3):161-72. J Clin Psychopharmacol. 1989. PMID: 2567741 Review.
Cited by
-
Meta-analysis of benzodiazepine use in the treatment of insomnia.CMAJ. 2000 Jan 25;162(2):225-33. CMAJ. 2000. PMID: 10674059 Free PMC article.
-
An assessment of short-acting hypnotics.Drug Saf. 1995 Oct;13(4):257-70. doi: 10.2165/00002018-199513040-00005. Drug Saf. 1995. PMID: 8573298 Review.
-
Rebound insomnia and newer hypnotics.Psychopharmacology (Berl). 1992;108(3):248-55. doi: 10.1007/BF02245108. Psychopharmacology (Berl). 1992. PMID: 1523276 Review.
-
A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to France.Pharmacoeconomics. 2001 Jan;19(1):69-78. doi: 10.2165/00019053-200119010-00005. Pharmacoeconomics. 2001. PMID: 11252547
-
A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience.Drug Saf. 1999 Dec;21(6):457-69. doi: 10.2165/00002018-199921060-00003. Drug Saf. 1999. PMID: 10612270 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical